- Home
- LTGO vs KURA Comparison
LTGO vs KURA Comparison
Compare LTGO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTGO | KURA |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2026 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LTGO | KURA |
|---|---|---|
| Price | $14.08 | $9.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $52.25 | $31.85 |
| AVG Volume (30 Days) | 359.2K | ★ 1.7M |
| Earning Date | 11-19-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $42.46 |
| Revenue Next Year | N/A | $116.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $14.60 | $7.36 |
| 52 Week High | $25.93 | $13.90 |
Technical Indicators
Market Signals| Indicator | LTGO | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 28.36 |
| Support Level | N/A | $8.45 |
| Resistance Level | $20.49 | $10.04 |
| Average True Range (ATR) | 1.23 | 0.41 |
| MACD | -0.21 | -0.10 |
| Stochastic Oscillator | 1.69 | 3.22 |
Price Performance
Historical ComparisonAbout LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.